Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 725-729

  Takahashi, Kayoko ^a   Saga, Yasushi ^a   Mizukami, Hiroyuki ^a   Takei, Yuji ^a   Machida, Shizuo ^a   Fujiwara, Hiroyuki ^a   Ozawa, Keiya ^a   Suzuki, Mitsuaki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cetuximab; Endometrial cancer; Lung metastasis; Lymph node metastasis; Peritoneal dissemination

Indexed keywords

CANCER ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; PERITONEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 70449389347     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000385     Document Type: Article

References (26)

1. Jemal A, Siegel R and Ward E: Cancer statistics, 2008. CA Cancer J Clin 58: 71-76, 2008.
2. Wolfson AH, Sightler SE and Markoe AM: The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 45: 142-146, 1992.
3. Lurain JR: Uterine cancer. In: Novak's Gynecology. 12th edition. Berek JS (ed). Williams & Wilkins, Baltimore, pp1057-1077, 1996.
4. Fujiwara H, Saga Y and Takahashi K: Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer 18: 165-167, 2007.
5. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003. (Pubitemid 46606324)
6. Normanno N, Maiello MR and De Luca A: Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 194: 13-19, 2003.
7. Yamazaki H, Fukui Y and Ueyama Y: Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8: 1816-1820, 1988.
8. Hirsch FR, Varella-Garcia M and Bunn PA Jr: Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807, 2003. (Pubitemid 46606235)
9. Niikura H, Sasano H and Matsunaga G: Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 26: 892-896, 1995.
10. Kawamoto T, Sato JD and Le A: Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341, 1983.
11. Masui H, Kawamoto T and Sato JD: Growth inhibition of human tumor cels in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002-1007, 1984. (Pubitemid 14152782)
12. Waksal H: Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 18: 427-436, 1999. (Pubitemid 30365321)
13. Kuramoto H, Tamura S and Notake Y: Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 114: 1012-1019, 1972.
14. Cunningham D, Humblet Y and Siena S: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
15. Gebbia V, Giuliani F and Valori VM: Cetuximab in squamous cell head and neck carcinomas. Ann Oncol (Suppl. 6): vi5-7, 2007.
16. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006. (Pubitemid 44497237)
17. Higashiyama S, Abraham JA and Miller J: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991. (Pubitemid 21926188)
18. Lynch TJ, Bell DW and Sordella R: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
19. Choi SH, Mendrola JM and Lemmon MA: EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26: 1567-1576, 2007.
20. Pao W, Miller V and Zakowski M: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004. (Pubitemid 39209661)
21. Perrotte P, Matsumoto T and Inoue K: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265, 1999. (Pubitemid 29085177)
22. Bruns CJ, Harbison MT and Davis DW: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747, 2000. (Pubitemid 30694960)
23. Bancroft CC, Chen Z and Yeh J: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548, 2002. (Pubitemid 34461606)
24. Luwor RB, Lu Y and Li X: The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441, 2005. (Pubitemid 40961766)
25. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985.
26. Takei Y, Mizukami H and Saga Y: Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer 120: 278-284, 2007. (Pubitemid 44956836)